Glaxo hit by US regulatory delay

GlaxoSmithKline has been hit by a delay to one of the six key drugs on which it was awaiting regulatory decisions this year.

GlaxoSmithKline has been hit by a delay to one of the six key drugs on which it was awaiting regulatory decisions this year.

The US Food and Drug Administration (FDA) moved the date when it will votes on whether to approve or reject GSK's experimental cancer drug Trametinib back to September 3rd 2013.

The Prescription Drug User Fee Act (PDUFA) date has been delayed extended by three months in order to allow the FDA more time to analyse and review the submission.

Chief executive Sir Andrew Witty last month said 2013 is "a key year for R&D pipeline delivery", with GSK counting on regulatory decisions on six drugs to help it boost sales by 1.0% this year.

The group filed for US approval for trametinib in August 2012 and in February 2013 for European regulatory approval.

Shares in GlaxoSmithKline had dipped 2.00p to 1,658.5p at 13.05 on the day of the announcement.

OH

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021